ClinicaliQ Trial Snapshot
- Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia — Recruiting • Phase II • NCT05070845.
- Review the linked registry entry for study design, population, endpoints, and operational status.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (>3 months and ≤12 months), or chronic (>12 months) ITP Conditions: Primary Immune Thrombocytopenia Interventions: PF-06835375 Lead Sponsor: Pfizer Planned Enrollment: 91 participants